Power Grid received the LoI on March 6, 2025, for a project that includes enhancing transformation capacity at the Kurnool-III substation, extending the C’peta substation, and establishing a 765kV double-circuit transmission line in Andhra Pradesh.

Emkay recommends buying Vedanta, targeting Rs 575 within a year, up from Rs 435.95. Vedanta, a large cap firm in the diversified sector, reported Q3 income up by 2.21% QoQ and 9.57% YoY, with a net profit of Rs 4876 crore. Hindustan Zinc, contributing 40% to EBITDA, aims to double its capacity by 2030.

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insulin, while Civica will manufacture and commercialize it, enhancing patient access to high-quality, affordable medication for diabetes management.

This presentation highlights five critical factors to help investors distinguish hidden gems from value traps

Foreign institutional investors (FIIs) have been rapidly offloading Indian equities, with February seeing notable sell-offs in sectors like capital goods, FMCG, financials, and oil & gas. Factors such as high valuations, attractive US bond yields, and Indian tax regimes are driving this exodus, significantly impacting market dynamics.

Axis Securities has an equal weight rating on HDFC Bank with a target price of Rs 2,000. HDFC Bank’s recent financials reflect a slight decline in total income, yet the bank maintains a solid net profit. Key drivers include improving NIMs, controlled costs, and strong asset quality. Risks involve potential slowdown in credit momentum and deposit mobilization challenges.

Sandip Sabharwal believes large-cap stocks will rise first before mid and small-caps catch up. He suggests allocating to NBFCs, banks, and infrastructure-oriented companies, while auto stocks may do well next year. He also sees potential in FMCG and metal sectors. He recommends Mahindra & Mahindra for autos and highlights the value in Bajaj Auto and tyre companies.

Laurus Labs has approved an investment of Rs 83.3 crore in the joint venture KRKA Pharma Pvt Ltd to establish a manufacturing facility targeting new markets, including India. KRKA d.d. will also invest Rs 86.7 crore, maintaining the 51:49 shareholding ratio with Laurus Labs.

Speaking in an ET Now interaction, Pandey emphasized that uncertainty regarding global growth and inflation remains, primarily due to ongoing trade disputes between the world’s two largest economies